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Background: Chronic eosinophilic pneumonia (CEP) is characterized by chronic eosinophilic infiltration of the lung.
It is dramatically responsive to corticosteroid treatment, but symptoms and radiopacities recur frequently after
tapering or discontinuing the medication. Fractional exhaled nitric oxide (FeNO) is a well-known noninvasive marker
of eosinophilic airway inflammation. The aim of this retrospective cohort study was to investigate the relationships
of FeNO with peripheral eosinophilia and the clinical state of CEP and its validity for predicting exacerbation of CEP.
Methods: Standard clinical and laboratory parameters, peripheral eosinophil percentage and count, and FeNO
level were measured in 18 patients with CEP at several assessment points over 1 year.
Results: FeNO level was positively correlated with peripheral eosinophil count (r = 0.341, P = 0.005) and
percentage (r = 0.362, P = 0.003). The median (IQR) FeNO levels were 79 (41–88) and 35 (26–49) ppb in uncontrolled
(13/74 measurements) and controlled (61/74 measurements) CEP, respectively (P = 0.010). The FeNO level of
66.0 ppb showed the largest area under the curve (0.835) for predicting exacerbation of CEP (sensitivity = 0.80,
specificity = 0.84).
Conclusion: FeNO may be useful for monitoring eosinophilic parenchymal inflammation and determining the
appropriate corticosteroid dose in CEP.
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Chronic eosinophilic pneumonia (CEP) is a rare disease
of unknown cause. It is characterized by chronic respira-
tory symptoms, bilateral peripheral lung opacities, pul-
monary eosinophilia, and/or peripheral eosinophilia. CEP
shows a dramatic response to corticosteroids. Symptoms
and radiopacities resolve rapidly after corticosteroid
treatment [1], but they recur frequently after tapering
or discontinuing the medication [1,2]. Most patients need
prolonged tailored treatment, similar to those with asthma* Correspondence: ctlee@snu.ac.kr
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unless otherwise stated.[3]. Therefore, a marker is required to assist in monitoring
and controlling CEP.
FeNO is an important marker of eosinophilic airway
inflammation in diseases such as asthma and nonasth-
matic eosinophilic bronchitis [4]. In asthma, FeNO level is
significantly correlated with eosinophil counts in broncho-
alveolar lavage (BAL) fluid, induced sputum, and airway
mucosal tissue [5-7]. It can identify patients with asthma
who are likely to benefit from corticosteroid treatment
and have reduced exacerbation rates [8-10]. Transition of
asthma from the well-controlled to the poorly controlled
state is associated with a rise in FeNO level [11]. Further,
maintenance doses of inhaled corticosteroids can be re-
duced without loss of asthma control on the basis of
FeNO level [12,13]. However, its value in eosinophilic par-
enchymal lung disease is unknown because inducible. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,




Age (years) 56 (41–68) 18





Current smoker 1 (5.6)
Ex-smoker 4 (22.2)
Pack-year history 25 (20–40)







History of tuberculosis 1 (5.6) 18
Laboratory findings














Alanine aminotransferase (IU/L) 17 (12–24) 17
Blood urea nitrogen (mg/dL) 10 (8–11) 17
Creatinine (mg/dL) 0.84 (0.66–0.98) 17
Spirometric results
Forced expiratory volume in 1
s/forced vital capacity ratio
76.0 (62–82) 15
% predicted forced expiratory
volume in 1 s
87.0 (67–100) 15
% predicted forced vital
capacity
86.0 (72–97) 15
*Data represent median (IQR) or number of patients (%).
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usually found in airway epithelium [14].
Recently, our group reported that FeNO level is signifi-
cantly higher in patients with acute eosinophilic pneu-
monia (AEP) than in those without AEP and decreases
during corticosteroid treatment, strongly suggesting that
FeNO level increases in eosinophilic parenchymal lung
diseases [15]. Further, FeNO level is lower in patients with
stable bronchiectasis than in those with asthma or chronic
obstructive lung disease, implying that FeNO has no role
in neutrophilic airway inflammation [16]. In this study, we
explored the significance of FeNO in the diagnosis and
management of CEP, an eosinophilic lung parenchymal
disease, by investigating its relationships with peripheral
eosinophilia and the clinical state of CEP and its validity
for predicting exacerbation of CEP.
Methods
Study design and definitions
This retrospective cohort study was conducted at Seoul
National University Bundang Hospital between November
2011 and October 2012. The Institutional Review Board
approved the study protocol and waived the need for in-
formed consent from patients (B-1210-174-105).
Diagnosis of CEP was based on the following criteria:
(i) pulmonary opacities with peripheral predominance
on chest radiography; (ii) peripheral eosinophilia ≥ 1000
cells/μL and/or alveolar eosinophilia ≥ 40% of the eosino-
phil count in BAL fluid; (iii) respiratory symptoms for over
2 weeks; and (iv) exclusion of known causes of eosi-
nophilic pneumonia (parasitic infection, drugs, or allergic
bronchopulmonary aspergillosis), eosinophilic granuloma-
tosis with polyangiitis (Churg–Strauss syndrome), and
hypereosinophilic syndrome [1].
Exacerbation was defined as reappearance of character-
istic infiltrates on chest radiography, recurrence of typical
clinical features, and increasing peripheral eosinophilia.
Uncontrolled CEP was defined as administration or
increasing dosage of corticosteroids due to diagnosis
or exacerbation of CEP. Controlled CEP was defined as
absence of symptoms regardless of corticosteroid dose.
Measurements
At each visit during the 1-year study period, we assessed
symptoms, chest radiographic findings, peripheral eosino-
phil count and percentage, and FeNO level. The recall
interval was individualized according to the clinical state:
most patients were reexamined every 2–3 months, but
some patients with uncontrolled CEP were recalled before
the scheduled appointment. Change in FeNO levels be-
tween visits was calculated at every assessment point, as
follows: ΔFeNO= FeNOn − FeNOn−1, where n and n − 1
represent the n-th and preceding visits, respectively.
Changes in peripheral eosinophil count (Δeosinophil count)and percentage (Δeosinophil percentage) were similarly
calculated.
FeNO level was measured by using a NIOX MINO
monitor (Aerocrine AB, Solna, Sweden), without the
nose clip, at an exhalation flow rate of 50 mL/s, according
to the American Thoracic Society (ATS)/European Res-
piratory Society (ERS) recommendation [17]. A FeNO
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inflammation and responsiveness to corticosteroids in
symptomatic patients and an increase over 10 ppb sug-
gested a significant ΔFeNO value [13].
Treatment
The parameters except FeNO level were used to tailor
the corticosteroid treatment. The initial regimen for
patients with newly diagnosed or uncontrolled CEP was
0.5 mg/kg/day of prednisolone. The dose was gradually
tapered according to the clinical state. Patients with
controlled CEP generally received a maintenance dose of
2.5- to 5-mg prednisolone daily. If no exacerbation event
occurred during 3 months of maintenance treatment,
the medication was discontinued. If symptom aggravation,
reappearance of radiopacities, and peripheral eosinophilia
were noted, suggestive of uncontrolled CEP, the dosage
was increased up to 0.5 mg/kg/day.
Statistical analysis
Data are presented as median (interquartile range [IQR])
values or number (%) of patients. FeNO levels and per-
ipheral eosinophil counts or percentages were analyzed
with Pearson correlation analysis. Continuous variables
were analyzed by using the Mann–Whitney U-test. The
Wilcoxon signed-rank test was used to evaluate para-
metric differences during an exacerbation event and after
corticosteroid administration. Receiver operating charac-
teristic (ROC) curve analysis was used to determine the
parametric values that best predicted exacerbation of
CEP. P < 0.05 was considered to be statistically signifi-
cant. All analyses were performed by using SPSS for
Windows (version 18.0, SPSS, Inc., Chicago, IL, USA).
Results
Baseline characteristics
Eighteen patients (10 men) were enrolled in the study;
fifteen patients had been diagnosed before the study
began. The median age was 56 (41–68) years (Table 1).Figure 1 Schematic of the study.One patient (5.6%) was a current smoker, and 17 patients
(94.4%) had never smoked or had stopped smoking. The
most common symptom was cough (n = 15), followed by
sputum production (n = 13). One patient (5.6%) had a his-
tory of pulmonary tuberculosis. The median peripheral
eosinophil percentage was 21.2% (11.6–42.3%) of the total
leukocyte count and median peripheral eosinophil count
was 1543 (771–4034) cells/μL. Seven patients underwent
BAL for diagnosis of CEP. The median eosinophil percent-
age in BAL fluid was 47% (15–65%).
Clinical course
Seven patients (38.9%) had controlled CEP throughout the
study. Ten exacerbation events occurred in nine patients
(50%), with one patient experiencing two episodes. In
total, 74 FeNO measurements were obtained from the 18
patients, including 10 measurements during exacerba-
tion events and three at diagnosis. Therefore, 13 FeNO
measurements were obtained during uncontrolled CEP
(Figure 1). Median time interval between patient visits
was 56 days (IQR 28–77). Median number of visits that
were attended by the patients was 4 (IQR 4–5).
Relationship of FeNO and peripheral eosinophilia
The median FeNO value, peripheral eosinophil percent-
age, and peripheral eosinophil count were 37 (11–165)
ppb, 5.1% (0.0–32.7%), and 283 (0–1938) cell/μL, respect-
ively. FeNO level was positively but weakly correlated with
peripheral eosinophil percentage (r = 0.362, P = 0.003)
and count (r = 0.341, P = 0.005). ΔFeNO was positively
and moderately correlated with Δeosinophil percentage
(r = 0.695, P < 0.001) and Δeosinophil count (r = 0.699,
P < 0.001) (Figure 2).
Relationship of FeNO and clinical state
The median FeNO levels were 79 (41–88) and 35 (26–49)
ppb in uncontrolled (13/74 measurements) and controlled
(61/74 measurements) CEP, respectively, showing a sig-
nificant difference between the clinical states (P = 0.010).
Figure 2 Relationship of FeNO level and peripheral eosinophilia in CEP. Scattergrams of FeNO level against peripheral eosinophil
percentage (A) and count (B) as well as ΔFeNO against Δeosinophil percentage (C) and Δeosinophil count (D) at every assessment point
are shown.
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higher in the uncontrolled state (17.5% [10.8–22.3%] vs.
3.8% [1.6–6.5%]; P < 0.001). The peripheral eosinophil
count showed a similar result (1239 [569–1608] cells/μL
vs. 250 [110–389] cells/μL; P < 0.001) (Figure 3).
In nine of the 10 exacerbation events, FeNO level was
measured after corticosteroid administration. The median
FeNO level significantly decreased after the treatment
(81 [67–95] ppb vs. 37 [32–44] ppb; P = 0.004]. In fiveevents, FeNO level was measured both before and after
the episode. Significant changes in FeNO level was noted
according to the clinical state of CEP (P = 0.022) (Figure 4).
There is one current smoker. His FeNO was measured
after one hour cessation of smoking according to previous
recommendation because smoking may decrease FeNO
level [18,19]. His FeNOs were measured two times in
stable state (29 and 33 ppb) which were within controlled
state IQR (26–49).
Figure 3 Parametric changes according to the clinical state of CEP. FeNO levels (A), peripheral eosinophil percentages (B), and peripheral
eosinophil counts (C) in the controlled and uncontrolled states of CEP are shown.
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The area under the curve (AUC) of FeNO level was
0.835 (95% confidence interval = 0.716–0.954). At the
cutoff level of 66 ppb, the sensitivity and specificity were
0.80 and 0.84, respectively. Further, the AUC of ΔFeNO
was 0.918; at the cutoff value of 8.4 ppb, the sensitivity
and specificity were 0.83 and 0.84, respectively (Figure 5
and Table 2). With regard to the ATS guidelines [20],
the sensitivity and specificity at the 50-ppb cutoff levelFigure 4 FeNO levels during exacerbation of CEP and after corticostewere 0.80 and 0.77, respectively, and those at the 10-ppb
cutoff level of ΔFeNO were 0.67 and 0.86, respectively
(Table 2).
The peripheral eosinophil percentage of 8.4% showed
the best sensitivity (0.89) and specificity (0.79) for predict-
ing exacerbation of CEP (AUC= 0.906). Further, the per-
ipheral eosinophil count of 451 cells/μL was the best cutoff
value (AUC = 0.923; sensitivity = 0.89; specificity = 0.83)
(Figure 5 and Table 2).roid treatment.
Figure 5 ROC curves of the studied parameters for predicting
exacerbation of CEP. ROC curves of FeNO level (black solid line),
ΔFeNO (gray solid line), peripheral eosinophil percentage (black
dotted line), and peripheral eosinophil count (gray dashed-dotted
line) are shown.
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In this study, we evaluated FeNO as a potential marker
of eosinophilic parenchymal inflammation and the clinical
course of CEP. We found a moderate positive correlation
between FeNO level and the degree of peripheral eosino-
philia. Uncontrolled CEP was associated with a signifi-
cantly higher FeNO level, and FeNO level increased
during exacerbation events and decreased after cortico-
steroid treatment. To the best of our knowledge, this is
the first study of FeNO in patients with CEP.
There are no clear diagnostic criteria for CEP. Most
authors do not recommend histopathologic proof for
establishing the diagnosis. Its diagnosis is based on sug-
gestive clinical features, characteristic radiographic appea-
rance, and peripheral eosinophilia [1,3,21]. We applied the
Marchand et al. [1] criteria in this study. BAL fluid ana-
lysis may be helpful in diagnosis but is not a prerequisiteTable 2 Diagnostic validity of the studied parameters for
exacerbation of CEP
Variable AUC Cutoff value Sensitivity Specificity
FeNO level 0.835 66.0 ppb 0.80 0.84
50.0 ppb* 0.80 0.77
ΔFeNO 0.918 8.4 ppb 0.83 0.84
10.0 ppb** 0.67 0.86
Peripheral eosinophil
percentage
0.906 8.4% 0.89 0.79
Peripheral eosinophil
count
0.923 451 cells/μL 0.89 0.83
*FeNO level > 50 ppb is indicative of eosinophilic inflammation and
corticosteroid responsiveness in symptomatic patients [20].
**ΔFeNO > 10 ppb indicates significant increase in FeNO level [20].[9,11]. The patients who did not undergo BAL not only
met the diagnostic criteria but also demonstrated the
clinical course of CEP.
CEP seems to show a pattern of waxing and waning
frequently. Most patients experience exacerbation events
when corticosteroid treatment is discontinued or tapered
[1,2]. In previous long-term follow-up studies, 59–69%
of the patients were still prescribed oral corticosteroid at
the last follow-up visit [1,2]. In this study, 72.2% (13/18)
used prednisolone at the last assessment point.
Numerous studies have demonstrated the relationships
of FeNO with eosinophilic airway inflammation [20] and
peripheral eosinophilia [22,23] in asthma. The positive
correlation between FeNO level and peripheral eosi-
nophilia in this study suggests that FeNO may reflect
eosinophilic inflammation in CEP. Further, FeNO level
increases during uncontrolled asthma and decreases
during treatment with anti-inflammatory agents [6,24];
increase in FeNO level also predicts loss of asthma control
[25]. In the present study, FeNO level showed a similar
trend.
Peripheral eosinophil counts do not necessarily indi-
cate the extent of eosinophilic involvement in affected
tissue [26]. The present results show that FeNO meas-
urement is not inferior to peripheral eosinophil percent-
age or count for monitoring eosinophilic inflammation in
CEP. In some ways, it is more useful because the measure-
ment method is completely noninvasive and easy to apply,
and results are obtained immediately [20]. Moreover, the
handheld FeNO monitor has the advantage of home-
based use [27].
The FeNO level of 66.0 ppb showed the largest AUC
with high sensitivity and specificity for predicting exacer-
bation of CEP. This value is near the ATS-recommended
cutoff level (>50 ppb) [20], which also showed good
sensitivity (80%) and specificity (77%). To account for each
patient’s state of eosinophilic inflammation, we also evalu-
ated ΔFeNO. The change in peripheral eosinophilia corre-
lated well with ΔFeNO. Furthermore, the ΔFeNO value
of 8.4 ppb showed good sensitivity and specificity for
predicting exacerbation of CEP, similar to the ATS-
recommended value of 10 ppb [20].
The present study has several limitations. First, all the
FeNO measurements were combined because of the
irregular assessment points in the small number of cases.
However, the FeNO levels were simultaneously measured
with the peripheral eosinophil and clinical parameters.
Second, the 1-year follow-up duration is not enough to
predict the long-term course of CEP. Third, the clinicians
were aware of each patient’s FeNO levels, although they
did not use them for tailoring the corticosteroid treat-
ment. Fourth, FeNO levels of only three patients were
measured at diagnosis of CEP. Additional FeNO data are
needed to determine the cutoff value for diagnosis of CEP.
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center. Prospective multicenter clinical trials are required
to analyze the association of symptoms, peripheral eosino-
philia, and FeNO.
Conclusions
FeNO may be a useful marker for monitoring eosino-
philic parenchymal inflammation and determining the
appropriate corticosteroid dose in CEP.
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